Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition

Fig. 5

Panel a and b shows that overweight/ Class 1 obese males had the longest progression free survival (PFS) among patients treated with monotherapy (a) and combination (b). Panel c and d shows that overweight/Class 1 obese patients with serum creatinine > = 0.9 mg/dL had the longest PFS among patients treated with monotherapy (c) and combination (d)

Back to article page